Cost of treating ventilator-associated pneumonia post cardiac surgery in the National Health Service: Results from a propensity-matched cohort study
- PMID: 29796064
- PMCID: PMC5956688
- DOI: 10.1177/1751143717740804
Cost of treating ventilator-associated pneumonia post cardiac surgery in the National Health Service: Results from a propensity-matched cohort study
Abstract
Background: Ventilator-associated pneumonia is associated with significant morbidity, mortality and healthcare costs. Most of the cost data that are available relate to general intensive care patients in privately remunerated institutions. This study assessed the cost of managing ventilator-associated pneumonia in a cardiac intensive care unit in the National Health Service in the United Kingdom.
Methods: Propensity-matched study of prospectively collected data from the cardiac surgical database between April 2011 and December 2014 in all patients undergoing cardiac surgery (n = 3416). Patients who were diagnosed as developing ventilator-associated pneumonia, as per the surveillance definition for ventilator-associated pneumonia (n = 338), were propensity score matched with those who did not (n = 338). Costs of treating post-op cardiac surgery patients in intensive care and cost difference if ventilator-associated pneumonia occurred based on Healthcare Resource Group categories were assessed. Secondary outcomes included differences in morbidity, mortality and cardiac intensive care unit and in-hospital length of stay.
Results: There were no significant differences in the pre-operative characteristics or procedures between the groups. Ventilator-associated pneumonia developed in 10% of post-cardiac surgery patients. Post-operatively, the ventilator-associated pneumonia group required longer ventilation (p < 0.01), more respiratory support, longer cardiac intensive care unit (8 vs 3, p < 0.001) and in-hospital stay (16 vs 9) days. The overall cost for post-operative recovery after cardiac surgery for ventilator-associated pneumonia patients was £15,124 compared to £6295 for non-ventilator-associated pneumonia (p < 0.01). The additional cost of treating patients with ventilator-associated pneumonia was £8829.
Conclusion: Ventilator-associated pneumonia was associated with significant morbidity to the patients, generating significant costs. This cost was nearer to the lower end for the cost for general intensive care unit patients in privately reimbursed systems.
Keywords: National Health Service costs; Ventilator-associated pneumonia; cardiac surgery; cost of ventilator-associated pneumonia.
Similar articles
-
Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center.Crit Care Med. 2003 May;31(5):1312-7. doi: 10.1097/01.CCM.0000063087.93157.06. Crit Care Med. 2003. PMID: 12771596
-
Cost of a ventilator-associated pneumonia in a shock trauma intensive care unit.Surg Infect (Larchmt). 2005 Spring;6(1):65-72. doi: 10.1089/sur.2005.6.65. Surg Infect (Larchmt). 2005. PMID: 15865552
-
Impact of ventilator-associated pneumonia on resource utilization and patient outcome.Infect Control Hosp Epidemiol. 2004 Dec;25(12):1090-6. doi: 10.1086/502349. Infect Control Hosp Epidemiol. 2004. PMID: 15636298
-
Long-Term Mortality After Pneumonia in Cardiac Surgery Patients: A Propensity-Matched Analysis.J Intensive Care Med. 2016 Jan;31(1):34-40. doi: 10.1177/0885066614523918. Epub 2014 Feb 27. J Intensive Care Med. 2016. PMID: 24578466 Review.
-
Effectiveness of dexmedetomidine versus propofol on extubation times, length of stay and mortality rates in adult cardiac surgery patients: a systematic review and meta-analysis.JBI Database System Rev Implement Rep. 2018 May;16(5):1220-1239. doi: 10.11124/JBISRIR-2017-003488. JBI Database System Rev Implement Rep. 2018. PMID: 29762314
Cited by
-
INHALE WP3, a multicentre, open-label, pragmatic randomised controlled trial assessing the impact of rapid, ICU-based, syndromic PCR, versus standard-of-care on antibiotic stewardship and clinical outcomes in hospital-acquired and ventilator-associated pneumonia.Intensive Care Med. 2025 Feb;51(2):272-286. doi: 10.1007/s00134-024-07772-2. Epub 2025 Feb 17. Intensive Care Med. 2025. PMID: 39961847 Free PMC article. Clinical Trial.
-
Systematic review of studies investigating ventilator associated pneumonia diagnostics in intensive care.BMC Pulm Med. 2021 Jun 9;21(1):196. doi: 10.1186/s12890-021-01560-0. BMC Pulm Med. 2021. PMID: 34107929 Free PMC article.
-
Improving Outcomes in Nosocomial Pneumonia: Recent Evidence and More Challenges.Pathogens. 2024 Jun 10;13(6):495. doi: 10.3390/pathogens13060495. Pathogens. 2024. PMID: 38921793 Free PMC article. Review.
-
Promoting subglottic secretion drainage: a quality improvement project in a UK critical care unit.BMJ Open Qual. 2021 May;10(2):e001269. doi: 10.1136/bmjoq-2020-001269. BMJ Open Qual. 2021. PMID: 34039618 Free PMC article. Review.
-
Comparison of Morbidity, Mortality, and Costs of VAP Patients with Non-VAP Patients in the Tertiary Referral Hospital of Kerman, Iran.Tanaffos. 2023 Jan;22(1):61-69. Tanaffos. 2023. PMID: 37920318 Free PMC article.
References
-
- American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388–416. - PubMed
-
- Muscedere J, Rewa O, McKechnie K, et al. Subglottic secretion drainage for the prevention of ventilator-associated pneumonia: a systematic review and meta-analysis. Crit Care Med 2011; 39: 1985–1991. - PubMed
-
- Kollef MH. Prevention of ventilator-associated pneumonia or ventilator-associated complications: a worthy, yet challenging, goal. Crit Care Med 2012; 40: 271–277. - PubMed
-
- The Direct Medical costs of Healthcare acquired infections in US hospitals and benefits of prevention, http://www.cdc.gov/HAI/pdfs/hai/Scott_CostPaper.pdf (accessed 21 October 2017).
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous